RxDoctor Payments Data

Jimmy Bui, DO

Internal Medicine · Oklahoma City, OKNPI 1649653833

Payments from drug & device makers

$432in general payments, 2019–2025

Across 10 payments — averaging $43.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$318
  • E.r. Squibb & Sons, L.L.C.$89
  • Pfizer$26

What the payments were for

  • Food & beverage$432100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson4$318
E.r. Squibb & Sons, L.L.C.5$89
Pfizer1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$432 in reported general payments places this provider in the 55th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$265,344
Medicare patients
773
Services billed
2,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban353$92,643
CopaxoneGlatiramer Acetate12$72,201
JardianceEmpagliflozin63$15,649
LinzessLinaclotide19$9,028
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,513
XareltoRivaroxaban27$6,729
JanuviaSitagliptin Phosphate24$6,579
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen155$4,975
MyrbetriqMirabegron13$4,491
Atorvastatin Calcium294$3,750
Gabapentin228$3,705
Isosorbide Dinitrate35$3,148
Amlodipine Besylate258$2,877
BrilintaTicagrelor14$2,675
Duloxetine Hcl82$2,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$92,643353 claims
Johnson & JohnsonXarelto$318$6,72927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →